IP Library › Granted Patent US 12,239,700
Granted Patent B2
US 12,239,700 · App. 18/187,133 · Granted Mar 4, 2025

Identification of variable influenza residues and uses thereof

Inventor: Darrell O. Ricke (Winchester, MA)
Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
A61K39/145A61K39/12A61K31/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,239,700
App. No.
18/187,133
Granted
Mar 4, 2025
Kind
B2
Abstract

Provided herein are universal prophylactic compositions for preventing infection with influenza viruses by directing the immune response to highly conserved regions of the virus. Also provided are universal therapeutic compositions for treating influenza infection by targeting the highly conserved regions. Methods for using the prophylactic and therapeutic compositions are also provided.

Claims (9)

1. An immunogenic composition comprising one or more polypeptides comprising an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO:3, wherein the one or more polypeptides each comprise mutations to alanine or glycine at each of residues 238, 239, 241, 242, and 243 relative to the amino acid sequence of SEQ ID NO:3.

2. The immunogenic composition of claim 1 , wherein the one or more polypeptides comprise an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:3.

3. The immunogenic composition of claim 1 , wherein the one or more polypeptides comprise an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:3.

4. The immunogenic composition of claim 1 , wherein the one or more polypeptides further comprise a mutation to alanine or glycine at each residue selected from the group consisting of 172, 174, 175, and 176 relative to SEQ ID NO:3.

5. The immunogenic composition of claim 1 , wherein the one or more polypeptides further comprise a mutation to alanine or glycine at each residue selected from the group consisting of 147, 151, 156, 158, 160, and 161 relative to SEQ ID NO:3.

6. The immunogenic composition of claim 1 , wherein the one or more polypeptides further comprise a mutation to alanine or glycine at each residue selected from the group consisting of 61, 64, 66, and 69 relative to SEQ ID NO:3.

7. The immunogenic composition of claim 1 , further comprising one or more polypeptides comprising an amino acid sequence at least 80% identical to the amino acid sequence SEQ ID NO:1, wherein the one or more polypeptides each comprise mutations to alanine or glycine at each of residues 159, 415, 419, 490, and 491 relative to the amino acid sequence of SEQ ID NO:1.

8. The immunogenic composition of claim 1 , further comprising one or more polypeptides comprising an amino acid sequence at least 80% identical to the amino acid sequence SEQ ID NO:5, wherein the one or more polypeptides each comprise mutations to alanine or glycine at each of residues 71, 86, 88, 90, 95 relative to the amino acid sequence of SEQ ID NO:5.

9. A method for immunizing a subject against infection with an influenza virus, inducing an immune response against influenza virus, or reducing an influenza virus infection in a subject in need thereof, comprising administering the immunogenic composition of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2023
From: RICKE, DARRELL O.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 063057/0069 →
Continuity (3)
Division 17186851 · Feb 26, 2021
Provisional Application 62983519 · Feb 28, 2020
Related Publication 20240207386A1 · Jun 27, 2024
References Cited (22)
US 7566458B2 · Yang · 2009 [cited by examiner]
US 8512711B2 · Lua · 2013 [cited by examiner]
US 9017694B2 · Jin et al. · 2015 [cited by applicant]
US 9393297B2 · Marshall · 2016 [cited by examiner]
US 10905756B2 · Eichmeyer et al. · 2021 [cited by applicant]
US 11939356B2 · Kwong · 2024 [cited by examiner]
US 20120014972A1 · Hodges et al. · 2012 [cited by applicant]
US 20210162037A1 · Jasny · 2021 [cited by examiner]
EP 3730620 · 2020 [cited by applicant]
WO 2008157419 · 2008 [cited by applicant]
WO 2010125461 · 2010 [cited by applicant]
WO 2018078053 · 2018 [cited by applicant]
WO 2014141125 · 2018 [cited by applicant]
WO 2019124557 · 2019 [cited by applicant]
WO 2019145475 · 2019 [cited by applicant]
WO 2019246363 · 2019 [cited by applicant]
WO 2020061443 · 2020 [cited by applicant]
International Search Report for PCT/US2021/019864, mailed Jun. 30, 2021. [cited by applicant]
Zolotarova et al., (2019) “Antigenic Site Variation in the Hemagglutinin of Pandemic Influenza A(H1N1)pdm09 Viruses between 2009-2017 in Ukraine,” Pathogens 2019, 8 (194): 1-13. [cited by applicant]
Opanda et al., (2020) “Assessing antigenic drift and phylogeny of influenza A (H1 N 1) pdm09 virus in Kenya using HA1 sub-unit of the hemagglutinin gene,” PLoS ONE 15(2): e0228029. [cited by applicant]
Korsun et al. (2020) “Genetic diversity of influenza A viruses circulating in Bulgaria during the 2018-2019 winter peason,” Journal of Medical Microbiology 2020;69:986-998. [cited by applicant]
Liu et al. (2021) “Molecular evolution and characterization of hemagglutinin and neuraminidase of influenza A (HiNl) pdm09 viruses isolated in Beijing, China, during the 2017-2018 and 2018-2019 influenza seasons,” Archi… [cited by applicant]